Trademark: 79032245
Word
PENUMBRA IS BRAIN
Status
Dead
Status Code
404
Status Date
Monday, July 25, 2016
Serial Number
79032245
Registration Number
3580586
Registration Date
Tuesday, February 24, 2009
Mark Type
5000
Filing Date
Tuesday, July 25, 2006
Published for Opposition
Tuesday, December 18, 2007
Cancellation Date
Monday, July 25, 2016

Trademark Owner History
Paion Deutschland GmbH - Original Registrant

Classifications
1 Biochemical preparations for scientific purposes; reagents for research
5 Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood cloning test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory use; Pharmaceutical preparations, namely, thrombolytic, fibrinolytic anti-coagulative, antithrombotical or neuroprotective substances for the treatment of blood clotting, cell protection and cell regeneration; products from biotechnological methods, namely, proteins for therapeutic and diagnostic use in the treatment and diagnosis of blood clotting disorders
10 Laboratory and analysis apparatus for medical, pharmaceutical and laboratory tests; medical devices, namely, coated catheters, medical stents, surgical implants comprising artificial materials; membranes intended for medical use, namely, filters for dialysis, hemofiltration
41 Educational services, namely, providing seminars, informational events and/or workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnostics
42 Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; licensing of intellectual property; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; preparation of expert opinions in the field of chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations, and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment, scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment
Color is not claimed as a feature of the mark.

Trademark Events
Apr 14, 2017
Total Invalidation Processed By The Ib
Feb 24, 2017
Notification Of Effect Of Cancellation Of Intl Reg Mailed
Feb 24, 2017
Death Of International Registration
May 27, 2016
Total Invalidation Of Reg Ext Protection Sent To Ib
May 27, 2016
Invalidation Processed
May 25, 2016
Total Invalidation Of Reg Ext Protection Created
Sep 25, 2015
Cancelled Section 71
Dec 13, 2013
New Representative At Ib Received
Jan 11, 2013
Final Decision Transaction Processed By Ib
May 29, 2009
Final Disposition Notice Sent To Ib
May 29, 2009
Final Disposition Processed
May 24, 2009
Final Disposition Notice Created, To Be Sent To Ib
Feb 24, 2009
Registered-Principal Register
Jan 15, 2009
Ttab Release Case To Trademarks
Jan 15, 2009
Opposition Terminated No. 999999
Jan 15, 2009
Opposition Dismissed No. 999999
May 23, 2008
Refusal Processed By Ib
Apr 18, 2008
Opposition Instituted No. 999999
Apr 17, 2008
Opposition Notice (Ib Refusal) Sent To Ib
Apr 17, 2008
Opposition Notice (Ib Refusal) Created
Dec 20, 2007
Extension Of Time To Oppose Received
Dec 18, 2007
Published For Opposition
Nov 28, 2007
Notice Of Publication
Nov 14, 2007
Law Office Publication Review Completed
Nov 14, 2007
Assigned To Lie
Oct 10, 2007
Approved For Pub - Principal Register
Jul 27, 2007
Amendment From Applicant Entered
Jul 27, 2007
Correspondence Received In Law Office
Jul 26, 2007
Assigned To Lie
Jul 10, 2007
Paper Received
Jun 12, 2007
Assigned To Examiner
Feb 1, 2007
Refusal Processed By Ib
Jan 10, 2007
Non-Final Action Mailed - Refusal Sent To Ib
Jan 10, 2007
Refusal Processed By Mpu
Dec 29, 2006
Non-Final Action (Ib Refusal) Prepared For Review
Dec 28, 2006
Non-Final Action Written
Dec 22, 2006
Assigned To Examiner
Dec 22, 2006
New Application Entered In Tram
Dec 21, 2006
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24